Your compliance team probably believes at least one dangerous myth about AI governance in healthcare. These misconceptions aren't just theoretical, they're creating legal exposure and eroding patient trust while you're focused elsewhere.
The myths persist because AI governance frameworks in healthcare remain immature. You're applying HIPAA Privacy Rule concepts designed for static records to dynamic, probabilistic systems. You're treating AI disclosure as optional when Pew Research Center data shows more than 70% of patients consider it extremely important for diagnostic decisions. And you're assuming consent mechanisms built for human interactions will somehow work for algorithmic ones.
Here's what you need to know.
Myth 1: HIPAA Compliance Means You're Covered for AI Use
Reality: HIPAA protections apply to patient data flowing through AI systems, but they don't address the unique risks these tools create.
Yes, information your clinicians enter into an AI scribe or diagnostic tool falls under the HIPAA Privacy Rule. But HIPAA doesn't require you to disclose AI use to patients, validate algorithmic accuracy, or document model training data sources. It doesn't address what happens when an AI transcription tool mishears "15 milligrams" as "50 milligrams" and your physician signs off without catching it.
The ongoing class action against Sutter Health and Memorial Care illustrates the gap. Plaintiffs alleged that medical staff used AI to record physician-patient communications without permission, violating state and federal law. The issue wasn't just HIPAA, it was consent, notice, and state wiretapping statutes that your HIPAA compliance program likely doesn't address.
You need governance controls that sit alongside HIPAA, not ones that assume HIPAA solves the AI problem. That means documented AI use policies, patient-facing disclosure protocols, and validation procedures for each AI tool before and after deployment.
Myth 2: Patients Don't Care About AI in Administrative Tasks
Reality: Survey participants want disclosure even when AI handles scheduling and prescription refills.
Your team might assume transparency requirements only apply to "serious" AI use, diagnosing conditions, analyzing scans, explaining lab results. But Pew Research Center found that most respondents want to know when AI takes notes during appointments, orders prescription refills, or schedules visits.
This matters because your risk assessment probably categorizes administrative AI as low-priority. You're deploying ambient documentation tools across hundreds of medical offices without patient-facing notices because you've classified them as internal workflow automation.
The distinction patients care about isn't clinical versus administrative. It's whether AI touches their personal health information and interactions. An AI scribe that mishears medication names creates the same safety risk as a diagnostic tool that misreads a scan. A scheduling algorithm that reveals appointment patterns to unauthorized parties violates privacy just as much as a leaked diagnosis.
Build your disclosure framework around information sensitivity and patient interaction, not your internal categorization of AI tools.
Myth 3: Verbal Consent at Check-In Is Sufficient
Reality: Nearly half of surveyed adults aren't sure if AI is used in their healthcare at all, which means your current consent process isn't working.
You might have updated intake forms to include a line about "digital tools and technologies" or trained front desk staff to mention AI verbally. But if half your patients don't know whether you're using AI, your consent mechanism is failing.
Effective consent for AI requires specificity. Patients need to understand which tools you're deploying, what role AI plays versus human judgment, how their data flows through these systems, and what alternatives exist if they decline.
Kaiser Permanente's approach with Abridge AI, requiring patient consent and having humans review AI-generated notes before entering them into medical records, represents a starting point. But your consent process should also document when patients opt out, provide clear escalation paths for concerns, and track which AI tools each patient has agreed to.
This isn't just about legal protection. It's about building the trust that makes patients comfortable sharing sensitive information in the first place.
Myth 4: If the Vendor Is Certified, Your Validation Work Is Done
Reality: You're accountable for fitness-for-purpose and ongoing accuracy, regardless of vendor certifications.
Your procurement team loves seeing SOC 2 Type II reports and HITRUST CSF certification from AI vendors. These matter, they confirm the vendor has basic security and privacy controls in place. But they don't tell you whether the tool accurately transcribes your cardiologists' technical terminology or whether it performs differently across patient demographics.
Clinicians deploying AI tools must validate them before rollout and continuously evaluate them in production. That means testing transcription accuracy against your specialty's vocabulary, monitoring error rates by use case, and documenting when the AI produces outputs that clinicians override or correct.
When Kaiser Permanente deployed Abridge AI across 40 hospitals and more than 600 medical offices in 2024, the human review requirement acknowledged this reality. The AI output is an input to the medical record, not the final word. Your governance framework should formalize that distinction with documented review protocols and error tracking.
Myth 5: Disclosure Will Scare Patients Away
Reality: Lack of transparency erodes trust more than honest disclosure about AI's role and limitations.
Your leadership team might worry that prominent AI disclosure will make patients uncomfortable or drive them to competitors. But the Pew data suggests the opposite, patients want to know, and they want to understand how AI fits into their care.
The trust problem isn't AI itself. It's uncertainty about how it's used, whether data gets sold to brokers, and whether doctors retain meaningful control over decisions. When you're transparent about AI's role, explain the safeguards you've built, and give patients real choices, you're building trust rather than destroying it.
This means your disclosure approach should answer the questions patients actually have: What does this AI tool do? What information does it access? Who reviews its output? What happens if I decline? How do you validate its accuracy?
What to Do Instead
Start with an AI inventory. Document every tool that touches patient data or clinical workflows, from ambient scribes to diagnostic assistants to administrative automation. For each tool, map the data flows, decision points, and human oversight mechanisms.
Then build your governance framework around three pillars: transparency, validation, and consent. Your transparency protocols should specify when and how you disclose AI use to patients. Your validation procedures should define pre-deployment testing requirements and ongoing monitoring for each tool category. Your consent mechanisms should give patients specific information and real alternatives.
Don't wait for a lawsuit to force these controls into place. The legal landscape is still forming, but patient expectations are already clear. More than 70% want disclosure for diagnostic AI, that's not a compliance edge case, it's your baseline requirement.
Your governance framework should reflect that reality, not the myths your team inherited from pre-AI compliance programs.
